Innoviva Inc
$ 22.21
-0.13%
13 Jul - close price
- Market Cap 1,641,507,000 USD
- Current Price $ 22.21
- High / Low $ 22.68 / 22.16
- Stock P/E 3.55
- Book Value 18.18
- EPS 6.26
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.51 %
- 52 Week High 25.14
- 52 Week Low 16.52
About
Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.
Analyst Target Price
$35.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-25 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-26 | 2024-11-06 | 2024-07-31 | 2024-05-08 | 2024-02-29 | 2023-11-01 | 2023-08-02 |
| Reported EPS | 0.47 | 1.944 | 1.08 | 0.77 | -0.7429 | 0.26 | 0.12 | -0.55 | 0.46 | 0.76 | 0.18 | 0.02 |
| Estimated EPS | 0.43 | 0.574 | 0.46 | 0.5 | 0.33 | 0.41 | 0.27 | 0.24 | 0.17 | 0.23 | 0.27 | 0.26 |
| Surprise | 0.04 | 1.37 | 0.62 | 0.27 | -1.0729 | -0.15 | -0.15 | -0.79 | 0.29 | 0.53 | -0.09 | -0.24 |
| Surprise Percentage | 9.3023% | 238.676% | 134.7826% | 54% | -325.1212% | -36.5854% | -55.5556% | -329.1667% | 170.5882% | 230.4348% | -33.3333% | -92.3077% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.56 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|
| Payment Date | None | None | None | None | None | None |
| Amount | $0.25 | $0.25 | $0.25 | $0.25 | $0.25 | $5.571428571 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: INVA
2026-07-08 05:58:00
This article analyzes Innoviva Inc. (INVA) with a focus on its impact on rotational strategy timing, highlighting weak near-term sentiment but long-term strength. It presents AI-generated trading strategies for different risk profiles, including position, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis. The analysis details support and resistance levels across near, mid, and long-term horizons for INVA.
2026-07-08 04:41:07
Innoviva (INVA) has been removed from several Russell indexes, potentially leading to increased short-term trading. Despite mixed stock momentum (up 11.98% YTD but down quarterly), analysis suggests the stock is undervalued with a P/E of 3.3x, significantly below both internal fair value estimates and industry averages. However, concerns remain about its concentrated royalty portfolio and declining net income.
2026-07-06 12:40:50
This article provides financial information for Innoviva, Inc. (SWB:HVE) focusing on its Enterprise Value to EBITDA forward. It is presented on the TradingView platform, which offers various financial tools and market data services.
2026-07-05 17:39:26
This page from TradingView provides a financial overview of Innoviva, Inc. (SWB:HVE) listed on the Stuttgart Stock Exchange, specifically focusing on its forward price-to-sales ratio. While the article highlights the financial metric, no specific values or analytical details are presented on this particular page. The rest of the content consists of navigation links and general platform information.
2026-07-04 03:39:26
This article provides the latest SEC filings information for Innoviva Inc (INVA), alongside comprehensive financial data and performance metrics. It includes details on market capitalization, income, sales, dividend information, various financial ratios, share performance, and analyst recommendations. The data indicates Innoviva Inc's current financial health and market position.
2026-07-03 13:39:35
Innoviva (INVA) was recently delisted from several Russell growth indices, including the Russell 2000 and 3000 Growth benchmarks, coinciding with its strategic shift towards building Nortiva Bio and the LYNX long-acting oral drug delivery platform. This removal may impact liquidity and introduce short-term volatility, but doesn't alter core operations, pipeline, or buybacks. Investors now face weighing potential funding needs for Nortiva, reduced index presence, and forecast earnings pressure, although the company maintains a cash-generative royalty and anti-infectives business.
